The FOXFIRE, SIRFLOX and FOXFIRE-Global (FF-SF-FFG) randomized studies evaluated the efficacy of combining first-line chemotherapy for metastatic colorectal cancer (mCRC) with selective internal radiotherapy (SIRT) using yttrium-90 resin microspheres in patients with liver metastases.  The studies… Read More
Interventional Oncology Practice Personnel
Timothy Clark, MD An interview with Timothy Clark, MD, Director, Interventional Radiology, Penn Presbyterian Medical Center, Division of Interventional Radiology, Department of Radiology, University of Pennsylvania. Why did you choose to move into interventional oncology? It has always been a… Read More
In his 2015 State of the Union address, President Obama committed to “launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes; and to give us all access to the personalized information we need to keep ourselves and our families healthier.” This… Read More
S. Samuels, MD, B. Schiro, MD, R. Gandhi, MD.  With a vibrant future ahead, Interventional Oncology (IO) will continue to provide the oncologic community and patients with cutting-edge treatments and proven therapies in a wide array of disease processes. Here we review the state of the major… Read More
Houston - 03/27/2017
Prostate cancer tumors get very little penetration by active immune cells and Padmanee Sharma M.D., Ph.D., would like to change that. As Professor of Genitourinary Medical Oncology and Immunology, she will be leading a clinical trial for stage IV prostate cancer on the… Read More
Marseille, France, March 30, 2017 - HalioDx SAS, an immuno-oncology diagnostic company, today announced that its R&D collaboration with QIAGEN N.V., a leading global provider of Sample to Insight solutions, has resulted in a U.S. Food and Drug Administration (FDA) 510(k) clearance for QIAGEN's… Read More
NEW YORK, March 27, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces it has reached a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (… Read More
OLATHE, Kan. – March 21, 2017 - Metactive Medical Inc. (Metactive), an early-stage company focused on developing embolization devices for the treatment of peripheral vascular and neurovascular diseases, today announced the issuance of US Patents 9,572,697 and 9,572,698 covering its Ballstent… Read More
Interventional oncology is a rapidly advancing field for interventional radiologists. These image-guided and minimally invasive procedures are increasing patient quality of life through easier recoveries with less burdensome procedures, including chemoembolization, Y90 therapies, radioembolization… Read More
WESTMINSTER, Colo., March 20, 2017 (GLOBE NEWSWIRE) -- Surefire Medical, Inc., the developer of site-specific delivery devices for the Interventional Oncology market, announced today that the company has received regulatory approval in Mexico for its Surefire Infusion Systems and Surefire Guiding… Read More